Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-09-30

FDA Approved: ENTECAVIR — Supplemental Application (AvKARE)

View source ↗

Summary

FDA approved a supplemental application for AvKARE's generic entecavir, authorizing its continued marketing for chronic hepatitis B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ENTECAVIR (ENTECAVIR)

Snippet

SUPPL AP for ENTECAVIR (ENTECAVIR)